Harold Burstein: ER-low tumors will require chemotherapy and endocrine therapy

Harold Burstein, Breast Cancer Specialist and Professor at Dana Farber Cancer Institute, shared a post by Annals of Surgical Oncology on X/Twitter, adding:

”Key clinical takeaway is that in contemporary breast cancer pathology, most ER-low (< 10%) tumors will require chemotherapy and endocrine therapy.”

Quoting Annals of Surgical Oncology’s post:

”April Issue: Defining the Biology of Estrogen Receptor-Low-Positive.”

Source: Harold Burstein/X and AnnalsSurgOncology/X